Accuray Incorporated (0H8I.L)
USD 1.56
(-2.78%)
USD 1.56
(-2.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 423.54 Million USD | -0.47% |
| 2022 | 425.55 Million USD | 1.4% |
| 2021 | 419.66 Million USD | 2.04% |
| 2020 | 411.25 Million USD | -3.75% |
| 2019 | 427.29 Million USD | 10.04% |
| 2018 | 388.31 Million USD | 17.64% |
| 2017 | 330.09 Million USD | -8.29% |
| 2016 | 359.93 Million USD | -12.08% |
| 2015 | 409.37 Million USD | 4.7% |
| 2014 | 390.99 Million USD | -1.42% |
| 2013 | 396.64 Million USD | 7.46% |
| 2012 | 369.09 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 423.54 Million USD | -0.47% |
| 2023 Q1 | 425.88 Million USD | 0.08% |
| 2023 Q2 | 428.69 Million USD | 0.66% |
| 2023 Q3 | 421.44 Million USD | -1.69% |
| 2023 Q4 | 423.54 Million USD | 0.5% |
| 2022 Q3 | 421.01 Million USD | 0.96% |
| 2022 Q4 | 425.55 Million USD | 1.08% |
| 2022 Q1 | 419.35 Million USD | -0.07% |
| 2022 Q2 | 417.02 Million USD | -0.56% |
| 2022 FY | 425.55 Million USD | 1.4% |
| 2021 Q3 | 417.82 Million USD | -1.57% |
| 2021 FY | 419.66 Million USD | 2.04% |
| 2021 Q1 | 430.01 Million USD | 4.56% |
| 2021 Q2 | 424.5 Million USD | -1.28% |
| 2021 Q4 | 419.66 Million USD | 0.44% |
| 2020 Q4 | 411.25 Million USD | 0.73% |
| 2020 Q2 | 400.36 Million USD | 0.78% |
| 2020 Q1 | 397.27 Million USD | -7.03% |
| 2020 Q3 | 408.27 Million USD | 1.98% |
| 2020 FY | 411.25 Million USD | -3.75% |
| 2019 Q2 | 423.47 Million USD | 0.17% |
| 2019 FY | 427.29 Million USD | 10.04% |
| 2019 Q4 | 427.29 Million USD | -0.66% |
| 2019 Q3 | 430.11 Million USD | 1.57% |
| 2019 Q1 | 422.77 Million USD | 8.88% |
| 2018 Q2 | 339.92 Million USD | 5.56% |
| 2018 Q1 | 322.02 Million USD | -2.44% |
| 2018 FY | 388.31 Million USD | 17.64% |
| 2018 Q4 | 388.31 Million USD | 8.32% |
| 2018 Q3 | 358.49 Million USD | 5.46% |
| 2017 Q1 | 345.3 Million USD | -4.06% |
| 2017 Q4 | 330.09 Million USD | -3.63% |
| 2017 FY | 330.09 Million USD | -8.29% |
| 2017 Q3 | 342.54 Million USD | -6.11% |
| 2017 Q2 | 364.82 Million USD | 5.65% |
| 2016 Q1 | 369.36 Million USD | -9.77% |
| 2016 Q4 | 359.93 Million USD | -3.09% |
| 2016 FY | 359.93 Million USD | -12.08% |
| 2016 Q3 | 371.39 Million USD | 0.78% |
| 2016 Q2 | 368.51 Million USD | -0.23% |
| 2015 FY | 409.37 Million USD | 4.7% |
| 2015 Q4 | 409.37 Million USD | -4.28% |
| 2015 Q3 | 427.67 Million USD | 3.69% |
| 2015 Q2 | 412.45 Million USD | 3.72% |
| 2015 Q1 | 397.67 Million USD | 1.71% |
| 2014 Q1 | 379.14 Million USD | -4.41% |
| 2014 Q2 | 391.61 Million USD | 3.29% |
| 2014 Q4 | 390.99 Million USD | 0.99% |
| 2014 Q3 | 387.17 Million USD | -1.13% |
| 2014 FY | 390.99 Million USD | -1.42% |
| 2013 Q2 | 390.02 Million USD | 3.05% |
| 2013 Q3 | 395.24 Million USD | 1.34% |
| 2013 Q4 | 396.64 Million USD | 0.35% |
| 2013 FY | 396.64 Million USD | 7.46% |
| 2013 Q1 | 378.49 Million USD | 2.55% |
| 2012 Q4 | 369.09 Million USD | -1.58% |
| 2012 FY | 369.09 Million USD | 0.0% |
| 2012 Q2 | 264.8 Million USD | 0.0% |
| 2012 Q3 | 375.03 Million USD | 41.62% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Phreesia, Inc. | 119.63 Million USD | -254.026% |
| Align Technology, Inc. | 2.45 Billion USD | 82.736% |
| Elevance Health Inc. | 69.52 Billion USD | 99.391% |
| AxoGen, Inc. | 101.16 Million USD | -318.678% |
| Boston Scientific Corporation | 15.6 Billion USD | 97.286% |
| CVS Health Corporation | 173.09 Billion USD | 99.755% |
| Cardinal Health, Inc. | 48.33 Billion USD | 99.124% |
| Centene Corporation | 58.68 Billion USD | 99.278% |
| DaVita Inc. | 14.87 Billion USD | 97.153% |
| HCA Healthcare, Inc. | 55.15 Billion USD | 99.232% |
| Hologic, Inc. | 4.02 Billion USD | 89.48% |
| Humana Inc. | 30.74 Billion USD | 98.622% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 76.144% |
| Laboratory Corporation of America Holdings | 8.83 Billion USD | 95.206% |
| Masimo Corporation | 1.67 Billion USD | 74.739% |
| McKesson Corporation | 69.04 Billion USD | 99.387% |
| Patterson Companies, Inc. | 1.89 Billion USD | 77.649% |
| Quest Diagnostics Incorporated | 7.6 Billion USD | 94.43% |
| ResMed Inc. | 2 Billion USD | 78.911% |
| Henry Schein, Inc. | 5.42 Billion USD | 92.186% |
| Teladoc Health, Inc. | 2.06 Billion USD | 79.502% |
| Universal Health Services, Inc. | 8.15 Billion USD | 94.806% |
| Veeva Systems Inc. | 1.26 Billion USD | 66.547% |
| Baxter International Inc. | 19.8 Billion USD | 97.862% |
| Becton, Dickinson and Company | 26.98 Billion USD | 98.43% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 79.281% |
| Danaher Corporation | 30.99 Billion USD | 98.634% |
| Stryker Corporation | 21.31 Billion USD | 98.013% |
| Medtronic plc | 39.56 Billion USD | 98.929% |